Varian has announced that five patients with brain cancer became the first patients in the United States to be treated using the company's HyperArc High-Definition Radiotherapy (HDRT), a new type of radiosurgery treatment, at the University of Alabama at Birmingham Comprehensive Cancer Center. HyperArc is designed to automate and simplify sophisticated treatments such as stereotactic radiosurgery (SRS) and make them available to more cancer patients around the world.
"We have been doing preclinical and clinical development of single isocenter radiosurgery for a decade," said John Fiveash, M.D., professor and vice chair for academic programs in the UAB Department of Radiation Oncology. "Over the last five years, our radiosurgery plan quality has improved to equal or exceed our Gamma Knife. Physicians and patients preferred the frameless and highly efficient delivery on our TrueBeam and Edge systems and our Gamma Knife was decommissioned June 2017. HyperArc planning automates much of the radiosurgery treatment planning strategies that we have implemented at UAB and could enable more clinics to perform higher quality radiosurgery for more patients."
"Working closely with leading institutions like UAB played an important role in the development of HyperArc," said Kolleen Kennedy, president of Varian's Oncology Systems business. "We value their continued contributions to the advancement of cancer care and we are excited that HyperArc treatments have now begun in the US."
HyperArc capitalizes on the unique capabilities of Varian's TrueBeam and EDGE treatment systems. HyperArc treatments allow clinicians the ability to deliver more compact radiation doses that closely conform to the size, shape, and location of tumors while sparing more surrounding healthy tissue. These advanced treatments can be delivered in a conventional treatment time slot. The treatment planning for HyperArc is supported by Varian's Eclipse treatment planning software.
For more information on HyperArc, visit www.varian.com/hyperarcBack To Top
First patients in U.S. treated with Varian HyperArc high-definition radiation therapy. Appl Rad Oncol.